Upadacitinib (trade name: Rinvoq) is an oral medication used to treat adults with moderate to severe rheumatoid arthritis (RA). It is a Janus kinase (JAK) inhibitor, which works by blocking the activity of certain proteins, called JAKs, which are involved in the inflammation process that leads to RA. Upadacitinib works by reducing the activity of these proteins, which helps to reduce inflammation and improve symptoms of RA. It may be used alone or in combination with other RA medications.
Upadacitinib, sold under the brand name Rinvoq, is a medication used to treat several inflammatory conditions. Here's a breakdown of its key points:
- Type of Drug: Janus kinase (JAK) inhibitor
- Brand Name: Rinvoq
- Uses:
- Moderate to severe rheumatoid arthritis (RA) in adults, often when other medications haven't been effective.
- Active psoriatic arthritis (PsA) in adults.
- Ankylosing spondylitis (AS) in adults.
- Moderate to severe ulcerative colitis (UC) in adults.
How it Works: Upadacitinib works by blocking the activity of certain enzymes called Janus kinases (JAKs) which are involved in the immune system's inflammatory response. By inhibiting JAKs, Upadacitinib helps reduce inflammation in the body.
Important Considerations:
- Upadacitinib is typically taken orally as a tablet once a day.
- It's crucial to be monitored by a healthcare professional while taking Upadacitinib due to potential side effects, including increased risk of infection, elevated liver enzymes, high blood pressure, and changes in blood cell counts.
- Upadacitinib may not be suitable for everyone, especially those with a history of serious infections or weakened immune system.
Here's some additional information:
- Upadacitinib is a relatively new medication that's still under investigation for other potential uses.
- If you're considering Upadacitinib, consult with a healthcare professional to discuss if it's the right treatment option for your specific condition and to understand the potential benefits and risks involved.